Open Trial of Nefazodone for Combat-Related Posttraumatic Stress Disorder
J Clin Psychiatry 1998;59(9):460-464
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Because of its ability to block 5-HT2 receptors
postsynaptically and inhibit 5-HT reuptake presynaptically and/or its enhancement of sleep
quality, nefazodone may be useful for symptom management in posttraumatic stress disorder
Method: Ten patients with combat-related DSM-IV posttraumatic stress
disorder (PTSD) entered an open-label 12-week trial of nefazodone with a 4-week follow-up,
beginning with 100 mg/day and increasing as necessary to achieve a maximal response or
until reaching a maximum dosage of 600 mg/day.
Results: Nefazodone was well tolerated, and no significant changes in
sexual function were reported. Based on Clinical Global Impressions-Improvement scores,
all 10 patients were rated as much improved. All PTSD symptoms (except self-reported PTSD
reexperiencing symptoms), sleep, and clinician-rated depression significantly improved at
week 12. At follow-up, significant changes were maintained, and self-reported PTSD
reexperiencing symptoms had also significantly improved. Effect sizes for all changed
symptoms were moderate to large at week 12 and at follow-up. Self-reported and
clinician-rated anger significantly improved. Self-reported depression failed to improve.
Improvement in social and occupational functioning was minimal.
Conclusion: These preliminary data suggest that nefazodone may be
effective in reducing the 3 primary PTSD symptom clusters and may be particularly helpful
in improving sleep and decreasing anger.